argenx

ARGX

Market cap $53.8B

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration agreement with argenx, a leading immunology innovation company. The collaboration will see argenx get access to Chai's AI platform and apply de novo antibody discovery across therapeutic targets. argenx has built one of biotechnology's most productive antibody engines, combining deep immunology expertise with a high-powered antibody engineering tea.

Here is how argenex SE (ARGX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.

Wells Fargo on Wednesday named the biotech stock a top Q3 tactical pick. An important catalyst looms for Argenx stock.

Argenx SE (NASDAQ:ARGX) stock has faced pressure after the company disclosed changes to the analysis plan for its ongoing Phase 3 Vyvgart study in myositis.

Argenx stock reversed course Wednesday, bumping above its 21-day line, as investors digested its myositis-focused R&D Day.

argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript

Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the second half of the year.